NCT04393506 2023-11-22
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
Clinical Trials
6 trialsNCT02721589 2023-02-28
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02742935 2023-02-27
A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03945604 2022-08-12
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03121716 2022-07-12
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02492789 2019-09-30
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
Atridia Pty Ltd.
Phase 1 Completed